Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
22 February 2021Website:
http://www.alumis.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
regular market | Tue, 17 Sep 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
ALMS Latest News
Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high selectivity and minimal off-target effects, potentially positioning it as a better alternative to the approved TYK2 inhibitor, Sotyktu. Despite strong midstage trial data and a solid cash runway, the highly competitive market and recent IPO status present significant investment risks.
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO and private placement raising gross proceeds of $250M – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a summary of recent corporate achievements and upcoming milestones.
– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission – – Pivotal Phase 3 program supported by positive Phase 2 STRIDE clinical data as well as ongoing open-label extension (OLE) study – – Topline data anticipated in 2026 – SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that patient dosing has commenced in the ONWARD Phase 3 clinical program.
What type of business is Alumis?
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
What sector is Alumis in?
Alumis is in the Healthcare sector
What industry is Alumis in?
Alumis is in the Biotechnology industry
What country is Alumis from?
Alumis is headquartered in United States
When did Alumis go public?
Alumis initial public offering (IPO) was on 22 February 2021
What is Alumis website?
https://www.alumis.com
Is Alumis in the S&P 500?
No, Alumis is not included in the S&P 500 index
Is Alumis in the NASDAQ 100?
No, Alumis is not included in the NASDAQ 100 index
Is Alumis in the Dow Jones?
No, Alumis is not included in the Dow Jones index
When was Alumis the previous earnings report?
No data
When does Alumis earnings report?
Next earnings report date is not announced yet